Skip to content
Screener

Alkermes ALKS Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$384.5MBeat by $5.6M
EPS$0.34Miss by $0.09
Revenue estimate$378.9M
EPS estimate$0.43

Next report

Oct 28, 2026 (in a month)
Revenue estimate$463.9M
EPS estimate-$0.08

Financials

Q4 2025

Income statement

See full
Revenue$384.5M-10.6%
Gross profit$338.3M-8.0%
Operating income$58.1M-64.3%
Net income$49.3M-66.3%
EPS (diluted)$0.29-66.7%

Balance sheet

See full
Cash & equivalents$388.6M+33.5%
Total debt$70.0M-7.3%
Total equity$1.8B+24.2%
Total assets$2.5B+21.0%

Cash flow

See full
Operating cash flow$170.1M-10.7%
CapEx--100%
Free cash flow$170.1M-5.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$4.62B-0.7%
Enterprise value$4.3B-3.1%
P/E19.1×+6.4×
P/S3.1×+0.1×

Profitability

See full
Gross margin86.7%+2.4pp
Operating margin17.2%-9.8pp
Net margin16.4%-7.2pp
FCF margin32.5%+6.5pp

Returns & leverage

See full
Return on equity14.7%-12.8pp
Debt / equity0×0.0×
Current ratio3.5×+0.5×

Segments

By product

See full
Vivitrol$124.1M-7.5%
Aristada And Aristada Initio$97.2M+0.6%

FAQ

When did Alkermes report Q4 2025 earnings?
Alkermes (ALKS) reported Q4 2025 earnings on February 25, 2026 before market open.
What were Alkermes's Q4 2025 revenue and EPS?
Alkermes reported revenue of $384.5M and eps of $0.34 for Q4 2025.
Did Alkermes beat estimates in Q4 2025?
Revenue beat the consensus estimate of $378.9M by $5.6M. EPS missed the consensus estimate of $0.43 by $0.09.
How did Alkermes's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 10.6% from $430.0M a year earlier and eps declined 67.3% from $1.04.
Where can I find Alkermes's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-068512) and the 10-K periodic report (0001193125-26-068925) directly on SEC EDGAR. The filing index links above go to sec.gov.